Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways

Biochemical and Biophysical Research Communications

Volumn 461, Issue 2, 2015, Pages 243-248

  Lozano Santos, Carol ^a   Amigo Jiménez, Irene ^b   Nova Gurumeta, Sara ^a   Pérez Sanz, Nuria ^a   García Pardo, Angeles ^b   García Marco, José A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Arsenic trioxide; CLL; Combined therapies; Fludarabine; Survival pathways; Synergistic effect

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ENZYME INHIBITOR; FLUDARABINE; GROWTH INHIBITOR; ORGANOARSENIC DERIVATIVE; OXIDE; PROTEIN KINASE B; VIDARABINE;

ADULT; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; GROWTH INHIBITORS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; OXIDES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 84937760507     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.04.007     Document Type: Article

References (30)

1. L. Pleyer, A. Egle, T.N. Hartmann, and R. Greil Molecular and cellular mechanisms of CLL: novel therapeutic approaches Nat. Rev. Clin. Oncol. 6 2009 405 418
2. T. Zenz, D. Mertens, and R. Küppers, et al., From pathogenesis to treatment of chronic lymphocytic leukaemia Nat. Rev. Cancer 10 2010 37 50
3. M. Hallek Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies Blood 122 2013 3723 3734
4. F.T. Awan, and J.C. Byrd New strategies in chronic lymphocytic leukemia: shifting treatment paradigms Clin. Cancer Res. 20 2014 5869 5874
5. C. Chung, and R. Lee Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia Pharmacotherapy 34 2014 1298 1316
6. K. Alimoghaddam A review of arsenic trioxide and acute promyelocytic leukemia Int. J. Hematol. Oncol. Stem Cell. Res. 8 2014 44 54
7. L. Zhou, Jian Hou, G. Chi-Fung Chan, and D. Man-Yuen Sze Arsenic trioxide for non acute promyelocytic leukemia hematological malignancies: a new Frontier J. Blood Dis. 1 2014 1018
8. P.R. Subbarayan, and B. Ardalan In the war against solid tumors arsenic trioxide needs partners J. Gastrointest. Cancer 45 2014 363 371
9. O. Merkel, C. Heyder, and D. Asslaber, et al., Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13 J. Mol. Med. 86 2008 541 552
10. J. Redondo-Muñoz, E. Escobar-Díaz, and M. Hernández del Cerro, et al., Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the PI3K/Akt pathway via JNK activation and PTEN upregulation Clin. Cancer Res. 16 2010 4382 4391
11. I. Amigo-Jiménez, E. Bailón, and E. Ugarte-Berzal, et al., Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide PLoS One 9 2014 e99993
12. A.B. Roecklein, and B. Torok-Storb Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes Blood 85 1995 997 1005
13. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
14. D. Rossi, M. Fangazio, and S. Rasi, et al., Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia Blood 119 2012 2854 2862
15. P.E. Czabotar, G. Lessene, A. Strasser, and J.M. Adams Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy Nat. Rev. Mol. Cell. Biol. 15 2014 49 63
16. A.D. Ramsay, and M. Rodriguez-Justo Chronic lymphocytic leukaemia-the role of the microenvironment pathogenesis and therapy Br. J. Haematol. 162 2013 15 24
17. J.A. Burger, and J.G. Gribben The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies Semin. Cancer Biol. 24 2014 71 81
18. S. Chiaretti, M. Marinelli, and I. Del Giudice, et al., NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment Leuk. Lymphoma 55 2014 2785 2792
19. K. Ishitsuka, J. Suzumiya, and M. Aoki, et al., Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma Haematologica 92 2007 719 720
20. M.T. Park, Y.H. Kang, and I.C. Park, et al., Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells Mol. Cancer Ther. 6 2007 82 92
21. H. Yan, Y.C. Wang, D. Li, and Y. Wang, et al., Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cδ Leukemia 21 2007 1488 1495
22. S. Takahashi Combination therapy with arsenic trioxide for hematological malignancies Anticancer Agents Med. Chem. 10 2010 504 510
23. F. Efficace, F. Mandelli, and G. Avvisati, et al., Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes J. Clin. Oncol. 32 2014 3406 3412
24. M.F. Arteaga, J.H. Mikesch, T.K. Fung, and C.S. So Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a transition to targeted therapies Br. J. Cancer 112 2015 413 418
25. A.M. Ramos, C. Fernández, and D. Amrán, et al., Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells Blood 105 2005 4013 4020
26. G. Tabellini, A. Cappellini, and P.L. Tazzari, et al., Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells J. Cell. Physiol. 202 2005 623 634
27. B.C. Bornhauser, L. Bonapace, and D. Lindholm, et al., Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway Blood 110 2007 2084 2091
28. M.C. Estaño, E. Calviño, and E. de Blas, et al., 2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways Biochem. Pharmacol. 84 2012 1604 1616
29. A.G. Buggins, and C.J. Pepper The role of Bcl-2 family proteins in chronic lymphocytic leukaemia Leuk. Res. 34 2010 837 842
30. K. Balakrishnan, J.A. Burger, and M. Fu, et al., Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia Neoplasia 16 2014 1036 1046